OPDIVO
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
6/8 — Strong
Priority Review
OPDIVO by Bristol Myers Squibb is pd-1 ligands, pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. Approved for melanoma. First approved in 2015.
OPDIVO (nivolumab) is a human IgG4 monoclonal antibody that blocks the PD-1 receptor on T cells, removing immune checkpoint inhibition and enabling anti-tumor immune responses. It is approved for multiple oncology indications including renal cell carcinoma, melanoma, NSCLC, colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma, primarily in combination with ipilimumab. The drug works by binding to PD-1 and preventing interaction with PD-L1 and PD-L2 ligands, thereby releasing T-cell proliferation and cytokine production previously suppressed by tumor microenvironments. OPDIVO represents a cornerstone immunotherapy in the competitive checkpoint inhibitor landscape and is indicated across multiple solid tumors.
$0.1BPart D
Mechanism of Action
PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab…
Indications (1)
Worked on OPDIVO at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.